16728-03-3

Usage

Uses

Used in Pharmaceutical Industry:
[1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique molecular structure and reactivity contribute to the development of new drugs and therapeutic agents.
Used in Drug Discovery and Development:
In the field of drug discovery and development, [1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL serves as a key intermediate in the creation of novel chemical entities with potential therapeutic applications. Its versatility in organic synthesis allows for the exploration of new drug candidates with improved efficacy and safety profiles.
Used in Production of Fine Chemicals:
[1-(4-METHOXY-PHENYL)-CYCLOPROPYL]-METHANOL is also utilized in the production of fine chemicals, which are high-purity chemicals used in various industries, including pharmaceuticals, agriculture, and materials science. Its role in this application is to provide a structural foundation for the synthesis of complex and high-value chemical products.

Upstream product

• 16728-01-1 1-(4-methoxyphenyl)-1-cyclopropanecarboxylic acid 
• 779206-51-8 1-(4-methoxyphenyl)cyclopropanecarboxylic acid methyl ester 
• 104-47-2 p-methoxybenzylnitrile 
• 16728-00-0 1-(4-methoxyphenyl)cyclopropane-1-carbonitrile 

Downstream Products

• 1026047-57-3 3,5-bis-[4-(1-trityloxymethyl-cyclopropyl)-phenoxy]-pyridine-4-carbaldehyde 
• 1027553-42-9 3,5-bis-(4-{1-[2-(2-ethoxy-ethoxy)-ethoxymethyl]-cyclopropyl}-phenoxy)-pyridine-4-carbaldehyde 
• 251996-71-1 methyl 4-{4-[1-[(triphenylmethoxy)methyl]cyclopropyl]phenoxy}thieno[2,3-c]pyridine-2-carboxylate 
• 1027730-36-4 4-(4-{1-[2-(2-ethoxy-ethoxy)-ethoxymethyl]-cyclopropyl}-phenoxy)-thieno[2,3-c]pyridine-2-carboxylic acid 
• 251996-75-5 4-(4-{1-[2-(2-ethoxy-ethoxy)-ethoxymethyl]-cyclopropyl}-phenoxy)-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 
• 251996-72-2 4-[4-(1-hydroxymethyl-cyclopropyl)-phenoxy]-thieno[2,3-c]pyridine-2-carboxylic acid methyl ester 
• 251996-70-0 4-{1-[(triphenylmethoxy)methyl]cyclopropyl}phenol 
• 1027428-91-6 4-[4-(1-hydroxymethyl-cyclopropyl)-phenoxy]-thieno[2,3-c]pyridine-2-carboxylic acid 
• 251996-74-4 4-{1-[2-(2-ethoxy-ethoxy)-ethoxymethyl]-cyclopropyl}-phenol 

Relevant academic research and scientific papers

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

Substituted Pyrrolidines and Methods of Use

The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, R4A, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Design of Potent and Druglike Nonphenolic Inhibitors for Catechol O-Methyltransferase Derived from a Fragment Screening Approach Targeting the S-Adenosyl- l -methionine Pocket

A fragment screening approach designed to target specifically the S-adenosyl-l-methionine pocket of catechol O-methyl transferase allowed the identification of structurally related fragments of high ligand efficiency and with activity on the described orthogonal assays. By use of a reliable enzymatic assay together with X-ray crystallography as guidance, a series of fragment modifications revealed an SAR and, after several expansions, potent lead compounds could be obtained. For the first time nonphenolic and small low nanomolar potent, SAM competitive COMT inhibitors are reported. These compounds represent a novel series of potent COMT inhibitors that might be further optimized to new drugs useful for the treatment of Parkinson's disease, as adjuncts in levodopa based therapy, or for the treatment of schizophrenia.

BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS

The present invention relates to benzimidazolyl-methyl urea derivatives of formula (I), wherein n, D, E, R1, R2, R3, R4, R6, R7, R8 and R9 are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Compounds advantageous in the treatment of central nervous system diseases and disorders

A series of novel compounds showing anticonvulsant activity is described. Such pharmaceutically active compounds may also show utility in the treatment of other central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia,

1-ADAMANTYLAZETIDIN-2-ONE DERIVATIVES AND DRUGS CONTAINING SAME

It is to provide a novel compound useful for preventing and/or treating diseases that involves 11β-hydroxysteroid dehydrogenase 1, particularly diabetes, insulin resistance, diabetes complication, obesity, dyslipidemia, hypertension, fatty liver, or metab

Cell adhesion-inhibiting antiinflammatory compounds

Compounds having Formula I are useful for treating inflammation. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of inhibiting/treating inflammatory diseases in a mammal.